Health & Environmental Research Online (HERO)


Print Feedback Export to File
2250918 
Technical Report 
Single-blind dose-ranging study of the effect of nebivolol in patients with angina pectoris 
Ulvenstam, G 
1991 
IPA/92/1001092 
REF 
eng 
IPA COPYRIGHT: ASHP A single blind study of the anti-anginal and anti-ischemic effects of nebivolol was conducted in 10 patients (mean age 61.4 yr) with stable angina pectoris who received 2.5, 5, or 10 mg nebivolol or placebo once daily for 2 wk. The mean anginal attack rate/day was reduced from one in the placebo run-in phase to 0.6 after 10 mg nebivolol. Concomitant nitroglycerin consumption was reduced from about 0.6 tablets/day to 0.3 during 5 or 10 mg nebivolol therapy. Compared with placebo, nebivolol prolonged time to onset of angina during exercise at all doses, with the greatest effect seen with the 5 mg dose. No patients withdrew from the study due to adverse drug effects. It was concluded that nebivolol has anti-anginal and anti-ischemic effects, with the optimum effect seen with 5 mg/day.